Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00234442 | Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer | terminated | Phase 2 | 47 | AstraZenecaINDUSTRY | 1 | Jun 30, 2009 | clinicaltrials |
| NCT00522639 | Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation(FDG-PET lung) | terminated | Phase 3 | 120 | Maastricht Radiation OncologyOTHER | 1 | Jun 30, 2009 | clinicaltrials |
| NCT00383331 | Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer | terminated | Phase 2 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 3, 2009 | clinicaltrials |
| NCT00259285 | Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer | terminated | Phase 2 | 10 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 2, 2009 | clinicaltrials |
| NCT00475657 | Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer | terminated | Phase 2 | 5 | Eli Lilly and CompanyINDUSTRY | 1 | May 29, 2009 | clinicaltrials |
| NCT00435578 | Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma | terminated | Phase 2 | 50 | Threshold PharmaceuticalsINDUSTRY | 1 | Apr 30, 2009 | clinicaltrials |
| NCT00174369 | MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 34 | PfizerINDUSTRY | 1 | Mar 17, 2009 | clinicaltrials |
| NCT00585845 | Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment | terminated | Phase 1 | 17 | Anza Therapeutics, Inc.INDUSTRY | 2 | Feb 20, 2009 | clinicaltrials |
| NCT00161278 | Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling | terminated | Phase 2 | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 30, 2008 | clinicaltrials |
| NCT00535015 | Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer | terminated | Phase 2 | 70 | AnaborexINDUSTRY | 2 | Jul 22, 2008 | clinicaltrials |
| NCT00607425 | Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening(SPIT-LC) | terminated | — | 40 | Scottsdale HealthcareOTHER | 0 | Jul 17, 2008 | clinicaltrials |
| NCT00263016 | Docetaxel in Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 50 | SanofiINDUSTRY | 1 | Mar 20, 2008 | clinicaltrials |
| NCT00061646 | Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 25 | AbbottINDUSTRY | 1 | Aug 14, 2007 | clinicaltrials |
| NCT00243204 | Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy | terminated | Phase 3 | 400 | Point TherapeuticsINDUSTRY | 1 | Jun 8, 2007 | clinicaltrials |
| NCT00290017 | Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy | terminated | Phase 3 | 400 | Point TherapeuticsINDUSTRY | 1 | Jun 8, 2007 | clinicaltrials |
| NCT00316433 | Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer | terminated | Phase 2 | 24 | Swedish Medical CenterOTHER | 1 | Apr 5, 2007 | clinicaltrials |
| NCT00064636 | Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | terminated | Phase 1 | 46 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Jun 30, 2009source: clinicaltrials